66 results
Page 2 of 4
424B5
drian
28 May 20
Prospectus supplement for primary offering
12:00pm
20-F/A
fl4m85a6g8hqf
30 Jul 19
Annual report (foreign) (amended)
7:00am
20-F/A
x3wi8s6iq4gl8y
5 Jun 19
Annual report (foreign) (amended)
7:00am
6-K
EX-1
dbm9y velm
28 May 19
Current report (foreign)
7:04am
6-K
EX-99
o823o e1b04i
7 Feb 19
As Representative of the several Underwriters
12:00pm
424B5
e2mc94sku945962vgdgx
5 Feb 19
Prospectus supplement for primary offering
5:12pm
424B5
uuvgzl hqdx56i3g9n
4 Feb 19
Prospectus supplement for primary offering
5:52pm
F-3
6mydfz4s
26 Dec 18
Shelf registration (foreign)
4:11pm
F-3
EX-5.1
blt4pnr1eq m4oyn8dmw
26 Dec 18
Shelf registration (foreign)
4:11pm
6-K
EX-99
nldoh0dy
8 Nov 18
BioLineRx Reports Significant Progress Across Oncology
7:00am
6-K
EX-99
qf57sxlolnz
8 Nov 18
BioLineRx Reports Significant Progress Across Oncology
7:00am
6-K
EX-10.4
40xnn6dyqtsmmvz
3 Oct 18
BioLineRx Increases Stake in BL-8040, its Lead Oncology
6:03am
6-K
yyvaocx fgm3q8c
3 Oct 18
BioLineRx Increases Stake in BL-8040, its Lead Oncology
6:03am
6-K
EX-10.3
fkq0ys o2rr4
3 Oct 18
BioLineRx Increases Stake in BL-8040, its Lead Oncology
6:03am
20-F/A
EX-4.33
z28ygr4
31 May 16
Annual report (foreign) (amended)
12:00am